Mobility Limitation: Clinical Trials

4 trials for Mobility Limitation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4
Phase 21Completed 1

Follow Mobility Limitation: new trials by email Literature Review of Mobility Limitation trials Research Report on Mobility Limitation

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
Parts A/B: Adrabetadex, Parts A/B: Sham Control - Niemann-Pick Disease, Type C
Phase 2 / Phase 3CompletedMandos LLC562015-10-012023-02-22
Optimizing Protein Intake in Older Americans With Mobility Limitations
Testosterone enanthate - Mobility Limitation
Phase 3CompletedBrigham and Women's Hospital922011-05-012021-07-29
Laser Light Visual Cueing for Freezing of Gait in Parkinson's Disease
Laser light (U-Step Walking Stabilizer with laser light) - Parkinson Disease
Phase 3CompletedParkinson's Disease Research, Education, and Clinical Center, Philadelphia222003-06-012012-01-02
A Comparison of Weighted Vest Exercise and Strength Training
InVEST (Increased Velocity Exercise Specific to Task) - Mobility Limitations, Aging
Phase 3CompletedNational Institute on Aging (NIA)1602001-07-012010-07-26

Narrower conditions

Cognitive Dysfunction (1)  ·  Deglutition Disorders (1)  ·  Disease (1)  ·  Niemann-Pick Disease, Type C (1)  ·  Parkinson Disease (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (4)  ·  Signs and Symptoms (4)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Nervous System Diseases (2)  ·  Basal Ganglia Diseases (1)  ·  Brain Diseases, Metabolic (1)  ·  Brain Diseases, Metabolic, Inborn (1)  ·  Cognition Disorders (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Digestive System Diseases (1)  ·  Esophageal Diseases (1)  ·  Gastrointestinal Diseases (1)  ·  Genetic Diseases, Inborn (1)  ·  Hemic and Lymphatic Diseases (1)

Interventions

2-Hydroxypropyl-beta-cyclodextrin (1)  ·  Cyclodextrins (1)  ·  Lasers (1)  ·  testosterone enanthate (1)

Sponsors

Brigham and Women's Hospital (1)  ·  Mandos LLC (1)  ·  National Institute on Aging (NIA) (1)  ·  Parkinson's Disease Research, Education, and Clinical Center, Philadelphia (1)

Countries

United States (4)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  New Zealand (1)  ·  Singapore (1)  ·  Spain (1)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)

Top investigators

Jonathan F. Bean, MD, MS (1)  ·  Lisette Bunting-Perry, PhD, RN (1)  ·  Shalender Bhasin, MD (1)

Results publications

PMID 19414509, PMID 19854420, PMID 21143443, PMID 21636073, PMID 22289248, PMID 29188864, PMID 29532075, PMID 30932132, PMID 33417663, PMID 40525490

NIH funding

2015 (1), K23AG019663 (1), R01AG037547 (1)